title: Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
authors.affiliation: Duke University Medical Center.
authors.forename: John P
authors.initials: JP
authors.lastname: Chute
authors.forename: Heather A
authors.initials: HA
authors.lastname: Himburg
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D006801:Humans; D000068877:Imatinib Mesylate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000517:prevention & control*; D016399:Lymphoma, T-Cell / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D020286:Pericytes / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate